Home / Market News / $RVMD
fiscal.ai Corporate Catalyst Impact 65/100 ● positive

HC Wainwright & Co. Maintains Buy Rating and Raises Price Target for Revolution Medicines

Nov 6, 2026, 7:03 PM UTC · Primary ticker $RVMD

HC Wainwright & Co. maintained a 'Buy' rating on Revolution Medicines and significantly increased its price target from $280 to $350. This upward revision by a prominent analyst firm suggests increased confidence in the company's future prospects and could positively influence investor sentiment.

On November 6, 2026, HC Wainwright & Co. reaffirmed its 'Buy' rating for Revolution Medicines (RVMD) and raised its price target by 25% to $350. This action signals strong analyst conviction in the company's valuation and potential growth, which is a positive short-term catalyst for RVMD's stock price. The increased price target, especially when compared to other recent analyst targets, suggests a growing consensus of optimism around the company's future performance. For traders, this presents an opportunity for potential upside, though the long-term implications will depend on the company's actual performance and pipeline developments.

$RVMD positive Analyst price target increase
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.